FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1610627369> ?p ?o ?g. }

• W1610627369 abstract "Paliperidone, risperidone's active metabolite, is now available in an oral formulation for daily use, and an intramuscular formulation for monthly administration may follow shortly.To compare effects of oral paliperidone with any other treatment for people with schizophrenia and schizophrenia-like illnesses.We searched the Cochrane Schizophrenia Group's Register (December 2006), and inspected references of identified studies for further trials. We contacted the manufacturers of paliperidone, the Food and Drug Administration, and authors of relevant trials for additional material.We included all relevant randomised trials.We independently selected and critically appraised studies, extracted data and analysed on an intention-to-treat basis. Where possible and appropriate, we calculated risk ratios (RR) and their 95% confidence intervals (CI) with the number needed to treat (NNT). We calculated Weighted Mean Differences (WMD) for continuous data.Five studies compared paliperidone with placebo. Fewer people left the studies early if they were randomized to paliperidone (n=1647, 5 RCTs, RR 0.68 CI 0.61 to 0.76, NNT 7 CI 6 to 9) and those receiving any dose of paliperidone were significantly more likely to have an improvement in global state (n=1420, 4RCTs, RR 0.69 CI 0.63 to 0.75, NNT 5 CI 4 to 6). People randomised to paliperidone were less likely to experience a recurrence of psychosis (n=1638, 5 RCTs, RR 0.45 CI 0.31 to 0.66, NNT 16 CI 13 to 26) than those allocated to placebo. Adverse effect data were not well reported but paliperidone does seem to produce a greater incidence of tachycardia than placebo (n=1638, 5 RCTs, RR1.88 CI 1.28 to 2.76, NNH 21 CI 11 to 90) and a consistent, significant elevation in serum prolactin was found for both men (n=413, 3 RCTs, WMD 27.68 CI 23.66 to 31.69) and women (n=252, 3 RCTs, WMD 87.39 CI 74.27 to 100.51). People receiving paliperidone were more likely to experience extrapyramidal disorders (n=1638, 5 RCTs, RR 2.21 CI 1.26 to 3.88, NNH 28 CI 12 to 129) and weight gain (n=769, 4 RCTs, WMD 1.07 CI 0.65 to 1.49, I-squared 78%) compared with those allocated to placebo. When compared with 10 mg/day olanzapine we found no differences between paliperidone and olanzapine for leaving in the short term (n=1332, 3 RCTs, RR 1.04 CI 0.89 to 1.21; 40% in both groups left by six weeks). Those receiving any dose of paliperidone were no more likely to have a recurrence of psychotic symptoms than those receiving 10 mg/day olanzapine (n=1327, 3 RCTs, RR 0.1.07 CI 0.64 to 1.76). Data from all three studies found paliperidone was less likely to produce a weight change than olanzapine (n=660, 3 RCTs, WMD -0.88 CI -1.38 to -0.37). Results for various movement disorders all favoured olanzapine. There are no clear data relating to social functioning, services use, quality of life, satisfaction and cost.In short-term studies, oral paliperidone is an antipsychotic that is more efficacious than placebo. We found its adverse effects to be similar to those of its parent compound, risperidone, with movement disorders, weight gain, and tachycardia all more common with paliperidone than placebo. In addition, paliperidone is associated with substantial increases in serum prolactin that may be associated with sexual dysfunction, although sexual functioning outcomes were not reported. At doses greater than 3 mg per day, oral paliperidone appears comparable in efficacy to oral olanzapine 10 mg per day. Regarding the critical comparison of oral paliperidone to risperidone, we have no information and are thus unable to determine if paliperidone has any advantages or disadvantages compared to its well-known parent compound." @default.
• W1610627369 created "2016-06-24" @default.
• W1610627369 creator A5023756758 @default.
• W1610627369 creator A5091376848 @default.
• W1610627369 date "2008-04-23" @default.
• W1610627369 modified "2023-09-25" @default.
• W1610627369 title "Oral paliperidone for schizophrenia" @default.
• W1610627369 cites W1552552087 @default.
• W1610627369 cites W1556485502 @default.
• W1610627369 cites W1591259115 @default.
• W1610627369 cites W1598602811 @default.
• W1610627369 cites W1610627369 @default.
• W1610627369 cites W1712504441 @default.
• W1610627369 cites W1788591795 @default.
• W1610627369 cites W1964442950 @default.
• W1610627369 cites W1965091910 @default.
• W1610627369 cites W1965351344 @default.
• W1610627369 cites W1967133683 @default.
• W1610627369 cites W1971290131 @default.
• W1610627369 cites W1977185679 @default.
• W1610627369 cites W1978040764 @default.
• W1610627369 cites W1980621268 @default.
• W1610627369 cites W1981367166 @default.
• W1610627369 cites W1984306621 @default.
• W1610627369 cites W1985133166 @default.
• W1610627369 cites W1989290949 @default.
• W1610627369 cites W1992181956 @default.
• W1610627369 cites W1992857340 @default.
• W1610627369 cites W1994462863 @default.
• W1610627369 cites W1995325939 @default.
• W1610627369 cites W1997478537 @default.
• W1610627369 cites W1998327293 @default.
• W1610627369 cites W1999373065 @default.
• W1610627369 cites W1999635835 @default.
• W1610627369 cites W1999689270 @default.
• W1610627369 cites W2000593746 @default.
• W1610627369 cites W2002383354 @default.
• W1610627369 cites W2007571007 @default.
• W1610627369 cites W2010906896 @default.
• W1610627369 cites W2011010877 @default.
• W1610627369 cites W2016880063 @default.
• W1610627369 cites W2017668590 @default.
• W1610627369 cites W2020844317 @default.
• W1610627369 cites W2021230488 @default.
• W1610627369 cites W2023839473 @default.
• W1610627369 cites W2026269345 @default.
• W1610627369 cites W2032712358 @default.
• W1610627369 cites W2034075204 @default.
• W1610627369 cites W2034861437 @default.
• W1610627369 cites W2038376893 @default.
• W1610627369 cites W2043075431 @default.
• W1610627369 cites W2043320066 @default.
• W1610627369 cites W2046466188 @default.
• W1610627369 cites W2048692599 @default.
• W1610627369 cites W2058610004 @default.
• W1610627369 cites W2058874144 @default.
• W1610627369 cites W2060902043 @default.
• W1610627369 cites W2064828122 @default.
• W1610627369 cites W2065817940 @default.
• W1610627369 cites W2069083329 @default.
• W1610627369 cites W2070504779 @default.
• W1610627369 cites W2077138902 @default.
• W1610627369 cites W2080756149 @default.
• W1610627369 cites W2080872700 @default.
• W1610627369 cites W2083794117 @default.
• W1610627369 cites W2085949979 @default.
• W1610627369 cites W2087050454 @default.
• W1610627369 cites W2087677233 @default.
• W1610627369 cites W2089465872 @default.
• W1610627369 cites W2092841720 @default.
• W1610627369 cites W2096775351 @default.
• W1610627369 cites W2096860525 @default.
• W1610627369 cites W2108450329 @default.
• W1610627369 cites W2113418300 @default.
• W1610627369 cites W2123232431 @default.
• W1610627369 cites W2126165527 @default.
• W1610627369 cites W2127872656 @default.
• W1610627369 cites W2128653662 @default.
• W1610627369 cites W2130235475 @default.
• W1610627369 cites W2131658797 @default.
• W1610627369 cites W2132649715 @default.
• W1610627369 cites W2135029321 @default.
• W1610627369 cites W2145422971 @default.
• W1610627369 cites W2149006846 @default.
• W1610627369 cites W2149639459 @default.
• W1610627369 cites W2151853736 @default.
• W1610627369 cites W2152240392 @default.
• W1610627369 cites W2154942897 @default.
• W1610627369 cites W2157563846 @default.
• W1610627369 cites W2157823046 @default.
• W1610627369 cites W2159155203 @default.
• W1610627369 cites W2163657155 @default.
• W1610627369 cites W2166604754 @default.
• W1610627369 cites W2169015656 @default.
• W1610627369 cites W2170683505 @default.
• W1610627369 cites W2183656574 @default.
• W1610627369 cites W2186828832 @default.
• W1610627369 cites W2332281813 @default.
• W1610627369 cites W2465435306 @default.
• W1610627369 cites W4251169171 @default.

• next